



This list of clinical research protocols relating to breast cancer is compiled for your convenience.

For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at http://www.cancer.gov/clinical_trials.

A searchable Web site developed by the National Library of Medicine is also available at <http://clinicaltrials.gov>.

SELECTED CLINICAL RESEARCH PROTOCOLS FOR BREAST CANCER

Diagnostic

ACOSOG-Z0010, GUMC-00152 Phase III Prognostic Study of Sentinel Node and Bone Marrow Micrometastases in Women With Stage I or IIA Breast Cancer

Chairperson: Armando E. Giuliano. Telephone: 310-829-8089. Lead organization: American College of Surgeons Oncology Group. Age range: over 18.

Fertility

MCC-13144 Preservation of Ovarian Function in Women Undergoing Adjuvant Therapy for Early Stage Breast Cancer (activation pending)

Chairperson: Pamela Munster, MD. Telephone: 813-903-6898. Lead organization: H. Lee Moffitt Cancer Center & Research Institute. Age range: 44 and under.

Genetics

NCI-00-C-0079 Comparative Genetic Study of Susceptibility Genotypes and Protein Expression in Healthy Women, Women at High Risk For Breast Cancer, and Women With Breast Cancer

Chairperson: Alan E. Anderson. Telephone: 423-544-9294. Lead organization: Center for Cancer Research. Age range: adult.

NCI-02-C-0212 Study of Clinical, Genetic, Behavioral, Laboratory, and Epidemiologic Characteristics of Individuals and Families at High Risk of Breast or Ovarian Cancer

Chairperson: Mark H. Greene.

Telephone: 301-594-7642. Lead organization: Center for Cancer Research. Age range: adult.

Prevention

KUMC-8508-01, NCI-P02-0217 Phase I Study of Indole-3-Carbinol For the Prevention of Breast Cancer in Non-Smoking Women at High Risk for Breast Cancer

Chairperson: Aryeh Hurwitz. Telephone: 913-588-6060. Lead organization: University of Kansas Medical Center. Age range: 18 to 70.

KUMC-HSC-7264-97, NCI-P00-0146 Phase II Randomized Chemoprevention Study of LY35-3381 Hydrochloride in Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia and at High Risk for Breast Cancer

Chairperson: Carol J. Fabian. Telephone: 913-588-7791. Lead organization: University of Kansas Medical Center. Age range: 18 and over.

MSKCC-99017, NCI-G99-1662 Phase II Randomized Study of Exemestane and Raloxifene in Postmenopausal Women With a History of Stage 0 (Ductal Carcinoma In Situ), I, II, or III Breast Cancer Who Have No Clinical Evidence of Disease

Chairperson: Maura Dickler. Telephone: 212-639-5456. Lead organization: Memorial Sloan-Kettering Cancer Center. Age range: 18 and over.

CLB-49901, SWOG-9630, SWOG-S9630 Phase III Random-

ized Study of Medroxyprogesterone Acetate Versus Observation for Prevention of Endometrial Pathology in Postmenopausal Women With Breast Cancer Treated With Adjuvant Tamoxifen

Chairperson: Leslie Kohman. Telephone: 315-464-6321. Lead organization: Cancer and Leukemia Group B. Age range: 18 and over.

NSABP-P-2 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer

Chairperson: Norman Wolmark. Telephone: 412-359-3336. Lead organization: National Surgical Adjuvant Breast and Bowel Project. Age range: 35 and over.

Screening

NCI-01-C-0009 Pilot Screening Study of Breast Imaging Outcome Measures in Women at High Genetic Risk of Breast Cancer

Chairperson: Ruthann M. Giusti. Telephone: 301-496-1611. Lead organization: Division of Cancer Epidemiology and Genetics. Age range: 25 to 56.

ACRIN-6652 Randomized Screening and Diagnostic Study of Digital Mammography Versus Screen-Film Mammography in the Detection of Breast Cancer in Women

Chairperson: Etta Pisano. Telephone: 919-966-6957. Lead organization: American College of Radiology Imaging Network. Age range: any age.

NCI-01-C-0008 Screening Study of Breast Imaging Outcome

Measures and Phase of Menstrual Cycle in Women at High Genetic Risk of Breast Cancer

Chairperson: Ruthann M. Giusti. Telephone: 301-496-1611. Lead organization: Division of Cancer Epidemiology and Genetics. Age range: 25 to 45.

NCI-02-C-0212 Study of Clinical, Genetic, Behavioral, Laboratory, and Epidemiologic Characteristics of Individuals and Families at High Risk of Breast or Ovarian Cancer

Chairperson: Mark H. Greene. Telephone: 301-594-7642. Lead organization: Center for Cancer Research. Age range: adult.

FCCC-02010, NCI-G02-2095 Study of Specific Biomarkers Based on Fine Needle Aspirates in Women at Increased Versus Normal Risk of Breast Cancer

Chairperson: Michael H. Torosian. Telephone: 215-728-2596. Lead organization: Fox Chase Cancer Center. Age range: 30 and over.

Supportive Care

SWOG-9342 Companion Study to Evaluate Late Cardiac Effects in Women With Node-Negative Breast Cancer Receiving Adjuvant Chemotherapy on Protocol SWOG-8897

Chairperson: Patricia A. Ganz. Telephone: 310-206-1404. Lead organization: Southwest Oncology Group. Age range: 18 and over.

CTSU, NSABP-B-34 Phase III Randomized Study of Adjuvant Clodronate With or Without Systemic Chemotherapy and/or Tamoxifen

in Women With Early-Stage Breast Cancer

Chairperson: Alexander H. G. Paterson. Telephone: 403-670-1707. Lead organization: National Surgical Adjuvant Breast and Bowel Project. Age range: not specified.

CLB-79809, NCI-P01-0184 Phase III Randomized Study of Zoledronate, Calcium, and Cholecalciferol (Vitamin D) to Prevent Bone Loss in Women With Breast Cancer Receiving Adjuvant Chemotherapy

Chairperson: Charles L. Shapiro. Telephone: 614-293-7530. Lead organization: Cancer and Leukemia Group B. Age range: 40 and over.

NCI-P01-0183, URCC-U2101 Randomized Study of Gabapentin For the Control of Hot Flashes and Other Vasomotor Symptoms in Women With Breast Cancer

Chairperson: Kishan J. Pandya. Telephone: 716-275-9319. Lead organization: University of Rochester Cancer Center. Age range: not specified.

NCI-P02-0209, SWOG-S9832 Randomized Study of the Effect of Telephone Counseling by Breast Cancer Survivors on Well-Being of Women With Recurrent Breast Cancer

Chairperson: Carolyn Gotay. Telephone: 808-586-2975, ext. 351. Lead organization: Southwest Oncology Group. Age range: not specified.

Adjuvant

NCI-G00-1836, UNC-9818 Phase II Study of Neoadjuvant Dox-

orubicin, Cyclophosphamide, and Paclitaxel With or Without Trastuzumab (Herceptin) Followed by Local Surgery With or Without Adjuvant Trastuzumab or Adjuvant Doxorubicin, Cyclophosphamide, Paclitaxel, and Trastuzumab in Women With Stage IIB, IIIA, IIIB, or IV Breast Cancer

Chairperson: Lisa Carey. Telephone: 919-966-4431. Lead organization: Lineberger Comprehensive Cancer Center. Age range: not specified.

AVENTIS-TAX-GMA-302, BCIRG-006, NCI-G01-1978 Phase III Randomized Study of Adjuvant Doxorubicin, Cyclophosphamide, and Docetaxel With or Without Trastuzumab (Herceptin) vs Trastuzumab, Docetaxel, and Either Carboplatin or Cisplatin in Women With HER2-neu-Expressing Node-Positive or High-Risk Node-Negative Operable Breast Cancer

Chairperson: Linnea Chap. Telephone: 310-829-5471. Lead organization: Jonsson Comprehensive Cancer Center. Age range: 18 to 70.

CLB-49909, E-N9831, NCCTG-N9831, SWOG-N9831 Phase III Randomized Study of Doxorubicin Plus Cyclophosphamide Followed By Paclitaxel With or Without Trastuzumab (Herceptin) in Women With HER2-Overexpressing Node-Positive Breast Cancer

Chairperson: Peter A. Kaufman. Telephone: 603-650-6700. Lead organization: Cancer and Leukemia Group B. Age range: 18 and over.

BIG-01-01, EORTC-10011, EU-20216 Phase III Randomized Study of Trastuzumab (Herceptin) in Women With HER2-Positive Primary Breast Cancer

Chairperson: Martine J. Piccart-Gebhart. Telephone: +32-2-5413206. Lead organization: Breast International Group. Age range: 18 and over.